Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-12-18

FDA Approved: INVOKAMET XR — Supplemental Application (Janssen Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for INVOKAMET XR (canagliflozin and metformin hydrochloride) submitted by Janssen Pharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • INVOKAMET XR (CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE)

Snippet

SUPPL AP for INVOKAMET XR (CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE)